 |
(2E, 4E, 6Z, 8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-l-yl) nona-2,4,6,8-tetraen-l-yl acetate |
|---|---|
| Trade Name | |
| Orphan Indication | Retinitis pigmentosa |
| USA Market Approval | USA |
| USA Designation Date | 2010-12-02 00:00:00 |
| Sponsor | Novelion Therapeutics, Inc.;887 Great Northern Way - Suite 250, Vancouver, British Columbia, V5T 4T5; |
Related Access Program